Sunset in Puerta del Sol, Madrid
Not in Madrido – In our latest ESMO20 Preview, we take a look at five emerging areas of cancer drug development involving early stage pipelines and highlight some important features and benefits to watch out for.
These topics won’t be on everyone’s radar, especially if the focus is on the big phase 3 trial readouts, yet they can teach us much about new combinations and future pipeline evolution.
Who’s actively moving novel approaches along and who’s sitting on their laurels?
After covering biomarkers to watch out for yesterday, we now take a dive into what’s looking interesting in terms of novel targets and the fresh new opportunities for the not faint of heart…
To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
A new dawn or a rapid sunset for epigenetics in oncology R&D?
Epigenetic therapies have had somewhat of a chequered history in oncology R&D, but new targets are always cropping up to tempt us to look further.
One emerging target we’ve come across – this is only the fourth mention here since January 2019 – is starting to gather steam with new players entering the landscape, as well as emerging preclinical and clinical evidence suggesting it might be well worth a serious look.
Here we look at the potential role this epigenetic target may have to play in a variety of difficult to treat cancers, as well as how it could enhance existing therapies in new combination approaches.
Could we combine these inhibitors with chemotherapy, with immunotherapy or DNA repair approaches? How does the therapeutic window stack up?
We look at the latest evidence from several sources and discuss where the opportunities might lie…
To learn more from our oncology analysis and get a heads up on insights and commentary an emerging area of epigenetics, subscribers can log-in or you can click to gain access to BSB Premium Content.
“Find a bit of beauty in the world today. Share it. If you can’t find it, create it. Some days this may be hard to do. Persevere.” ~ Lisa B. Adams
In the first part of the review on novel targets in hematologic malignancies, we covered five key areas in detail relating to emerging new agents around BTK, BRD, BET, and E3 ligase modulators (CELMoDs).
Continuing our look at some additional novel targets and agents in early development in hematologic malignancies, in part two of this series we explore four additional areas that piqued our interest.
These mostly involve either small molecules or monoclonal antibodies.
In the next series, we shall look at emerging immunotherapy related targets, but for now there’s plenty of targeted therapies to focus on!
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.